Article Text

Download PDFPDF
We need to talk about brain donation
  1. Martin R Turner
  1. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  1. Correspondence to Professor Martin R Turner, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; martin.turner{at}ndcn.ox.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

How is any neurological disease defined? Detailed medical case reports are accessible in publications going back at least 200 years. Pre-eminent figures of the 19th century, such as Gowers and Charcot (to name only two among many across the globe), were great observers and painstaking taxonomists. It is testament to the detail of many of the descriptions from this period, including exquisite drawings in many cases, that the neurological syndromes are often easily recognisable and distinguishable today without the advances in molecular biology and neuroimaging that emerged only over the last 50 years. These original pioneers grounded their clinical observations alongside (necessarily) postmortem histology. Neuropathology continues to be the ‘gold standard’ in delineating and finding common molecular pathways for what, in life, are often syndromes with considerable clinical overlap.

In this issue, Cullinane et al present a review of the core histopathology of the neurodegenerative disorders (accompanied by an excellent macroscopic tissue video demonstration).1 Specific protein aggregates are undoubtedly the common thread across the neurodegenerative disorders. Just as association and causation are a pitfall of epidemiology, it is important to consider that protein aggregation might, to some extent, reflect those cells doing their best to mitigate other primary drivers of neurodegeneration. After all, those cells failing in that task won’t be visible. For what are essentially disorders whose incidence increases with age, there is a broader concept of loss of protein ‘quality control’ or ‘cellular tolerance’ in neurodegeneration. This is self-evident in monogenetically mediated forms where gene variants are present from the time of conception, yet the disease is not manifest …

View Full Text

Footnotes

  • Contributors MRT is the sole author.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed by Huw Morris, London, UK.

Linked Articles

  • Review
    Patrick W Cullinane Sarah Wrigley Jacy Bezerra Parmera Fernanda Valerio Thomas O Millner Karen Shaw Eduardo De Pablo-Fernandez Thomas T Warner Zane Jaunmuktane

Other content recommended for you